Report interim data for DISC-0974 in chronic kidney disease anemia

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 23 Jan 2023
Due: 31 Dec 2023
Delivered: December 2023

Deadline
Met
Late
Not met
Today

What the company said

“Interim data expected in ’23”

SourceDisc Medicine, Inc. Form 8-K press release, 2023-01-23
FilingSEC filing index
Deadline as stated’23
Deadline used31 Dec 2023, the last day of the stated period
TypeProject
Permanent referenceKI-C-2023-IRON-002125
Cite as https://keptindex.org/c/KI-C-2023-IRON-002125/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company reported interim data for the DISC-0974 Phase 1b/2 clinical trial in patients with non-dialysis dependent chronic kidney disease in December 2023, meeting the 2023 deadline.

A
Disc Medicine, Inc. 10-K filed 2024-03-21 Regulatory filing · published 21 Mar 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC
“initiated a separate Phase 1b/2 placebo controlled, single/multiple ascending dose clinical trial in patients with non-dialysis dependent CKD and anemia in February 2023. Interim data from these two trials was presented in December 2023.” ✓ confirmed on the page

Market reaction: the shares moved -10.3% against the S&P 500 over the three sessions around the disclosure (20 Mar 2024 to 25 Mar 2024). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +731 days
3 versions

Version 1 · original · stated 23 Jan 2023

Deadline 31 Dec 2023 (“’23”) · wording expected
Version 2 · stated 4 Nov 2024

Deadline 31 Dec 2024 (“Q4 2024”)

“DISC-0974: Complete Phase 1b data in MF anemia Q4 2024”
Source for this version
Version 3 · stated 10 Jan 2025

Deadline 31 Dec 2025 (“H2 2025”) · wording expected

“Data from higher doses and multiple dose cohorts of a phase 1b study of DISC-0974 in anemia of chronic kidney disease (CKD) expected H2 2025”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Interim data for DISC-0974 in chronic kidney disease anemia
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.